TG Therapeutics (TGTX) News Today

TG Therapeutics, Inc. (NASDAQ: TGTX) — The stock is trading higher after a mix of analyst upgrades and company results: HC Wainwright sharply raised multi-quarter and multi-year EPS forecasts and kept a Buy/$70 target, while TG’s Q1 report showed revenue upside driven by strong Briumvi sales and an upgraded 2026 revenue view despite a modest EPS miss. These factors together are supporting bullish sentiment and lifted the share price to fresh highs.

• Positive Sentiment: HC Wainwright materially raised EPS estimates across 2026–2030 (examples: FY2026 to $1.30 from $0.94; FY2027 to $2.45; FY2030 to $4.88) and reiterated a Buy rating with a $70 price target — a clear analyst catalyst for upside expectations. (no direct link)
• Positive Sentiment: Company reported strong Briumvi sales and raised its 2026 revenue guidance, which investors are viewing as validation of commercial momentum and top-line durability. TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
• Positive Sentiment: Retail and momentum flows pushed the stock to a fresh 52-week high despite the EPS miss, indicating strong market appetite for the story and follow-through buying. TGTX stock hits fresh 52-week high – here’s why retail is bullish despite Q1 earnings miss
• Neutral Sentiment: Full Q1 call/transcript is available for investors who want detail on guidance drivers, channel inventory, and commercial cadence — useful for due diligence but not an immediate directional driver. TG Therapeutics (TGTX) Q1 2026 Earnings Transcript
• Negative Sentiment: Q1 EPS missed consensus (reported ~$0.17 vs. ~0.23 expected), which is a short-term negative on profitability metrics; however, management’s revenue/guide beat and upgraded analyst forecasts have largely offset the reaction. TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View

Bottom line for investors: near-term bullishness is driven by upgraded analyst forecasts and stronger-than-expected Briumvi revenue/updated guidance; watch upcoming quarterly cadence and whether future EPS/earnings execution meets the higher analyst expectations that underlie the $70 target.